Read by QxMD icon Read

arb cancer

Victoria Mandilaras, Nathaniel Bouganim, Hui Yin, Jamil Asselah, Laurent Azoulay
BACKGROUND: Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are commonly used antihypertensives. Recently, these drugs have been associated with a protective effect against pancreatic cancer, but data on this putative association remain limited. Thus, the objective of this study was to determine whether the use of ACEIs and/or ARBs is associated with a decreased risk of pancreatic cancer. METHODS: We conducted a population-based cohort study, using a nested case-control analysis within the UK Clinical Practice Research Datalink population...
November 15, 2016: British Journal of Cancer
David Gaffney, Bill Small, Henry Kitchener, Sang Young Ryu, Akila Viswanathan, Ted Trimble, Al Covens, Sarikapan Wilailak, Arb-Aroon Lertkhachonsuk, Chomporn Sitathanee, Umesh Mahantshetty, Brandon Fisher, Susan Springer, Thomas Pollatz, Antonius Spiller, Monica Bacon, Anuja Jhingran
Eighty-seven percent of cervix cancer occurs in less-developed regions of the world, and there is up to an 18-fold difference in mortality rate for cervix cancer depending on the region of the world. The Cervix Cancer Research Network (CCRN) was founded through the Gynecologic Cancer InterGroup with the aim of improving access to clinical trials in cervix cancer worldwide, and in so doing improving standards of care. The CCRN recently held its first international educational symposium in Bangkok. Sixty-two participants attended from 16 different countries including Pakistan, India, Bangladesh, Thailand, Malaysia, Singapore, Philippines, Taiwan, China, Vietnam, Korea, Japan, Columbia, Brazil, Canada, and the United States...
November 2016: International Journal of Gynecological Cancer
Sari Toropainen, Einari A Niskanen, Marjo Malinen, Päivi Sutinen, Minna U Kaikkonen, Jorma J Palvimo
Androgen receptor (AR) is a male sex steroid-activated transcription factor (TF) that plays a critical role in prostate cancers, including castration-resistant prostate cancers (CRPC) that typically express amplified levels of the AR. CRPC-derived VCaP cells display an excessive number of chromatin AR-binding sites (ARBs) most of which localize to distal inter- or intragenic regions. Here, we analyzed direct transcription programs of the AR in VCaP cells using global nuclear run-on sequencing (GRO-seq) and integrated the GRO-seq data with the ARB and VCaP cell-specific TF-binding data...
September 19, 2016: Scientific Reports
Yun F Qian, Wei G Xu, Jun Wu
INTRODUCTION: Some studies reported that Angiotensin receptor blockers (ARBs) reduced the risk of breast cancer. However, other studies did not show similar results. EVIDENCE ACQUISITION: The Pubmed and Embase databases were searched. The strength of the association between ARBs and the risk of breast cancer was measured by odds ratio (OR) and 95% confidence interval (CI). EVIDENCE SYNTHESIS: Eight eligible literatures with 1994880 individuals were enrolled in this meta-analysis...
September 15, 2016: Panminerva Medica
Koray Tascilar, Laurent Azoulay, Sophie Dell'Aniello, Dorothee B Bartels, Samy Suissa
BACKGROUND: A meta-analysis reported an 8% increased risk of cancer with the use of angiotensin receptor blockers (ARBs), but subsequent meta-analyses and observational studies did not confirm this risk. However, telmisartan comprised 85% of the data in the original meta-analysis. Thus, the objective of this study was to determine whether the use of telmisartan, compared with other ARBs, is associated with an increased risk of cancer. METHODS: We used the United Kingdom Clinical Practice Research Datalink to assemble a cohort of all patients newly treated with ARBs between 2000 and 2008, and followed until December 2010...
August 24, 2016: American Journal of Hypertension
Hadar Goldvaser, Shulamit Rizel, Daniel Hendler, Victoria Neiman, Daniel Shepshelovich, Tzippy Shochat, Aaron Sulkes, Baruch Brenner, Rinat Yerushalmi
PURPOSE: To evaluate the association between angiotensin receptor blocker (ARB) usage and breast cancer characteristics and outcomes. METHODS: All patients who were treated in our institute for estrogen receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer between April 2005 and March 2012 and whose tumors were sent for Oncotype-DX analysis were included. Medical records were retrospectively reviewed. Data regarding ARB usage were retrieved...
2016: Oncology
María S Islas, Alicia Luengo, Carlos A Franca, Mercedes Griera Merino, Laura Calleros, Manuel Rodriguez-Puyol, Luis Lezama, Evelina G Ferrer, Patricia A M Williams
The coordination compound of the antihypertensive ligand irbesartan (irb) with copper(II) (CuIrb) was synthesized and characterized by FTIR, FT-Raman, UV-visible, reflectance and EPR spectroscopies. Experimental evidence allowed the implementation of structural and vibrational studies by theoretical calculations made in the light of the density functional theory (DFT). This compound was designed to induce structural modifications on the ligand. No antioxidant effects were displayed by both compounds, though CuIrb behaved as a weak 1,1-diphenyl-2-picrylhydrazyl radical (DPPH(·)) scavenger (IC50 = 425 μM)...
October 2016: Journal of Biological Inorganic Chemistry: JBIC
Jian Shen, Yan-Mei Huang, Min Wang, Xue-Zhi Hong, Xin-Nan Song, Xia Zou, Yan-Hong Pan, Wei Ling, Min-Hui Zhu, Xiao-Xi Zhang, Yi Sui, Hai-Lu Zhao
INTRODUCTION: The effects of renin-angiotensin system blockade with angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II type 1 receptor blockers (ARBs) on cancer remain inconsistent. METHODS: We searched existing databases from 1960 to August 2015, for randomised controlled trials and observational studies (case-control studies and cohort studies) of ARB/ACEI therapy with a minimal one year of follow-up. Outcomes were incidence and mortality of cancer...
July 2016: Journal of the Renin-angiotensin-aldosterone System: JRAAS
Zachary S Morris, Sandeep Saha, William J Magnuson, Brett A Morris, Jenna F Borkenhagen, Alisa Ching, Gayle Hirose, Vanesa McMurry, David M Francis, Paul M Harari, Rick Chappell, Stuart Tsuji, Mark A Ritter
BACKGROUND: Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are commonly used antihypertensive medications that have been reported to affect aberrant angiogenesis and the dysregulated inflammatory response. Because of such mechanisms, it was hypothesized that these medications might affect the tumor response to neoadjuvant radiation in patients with rectal cancer. METHODS: One hundred fifteen patients who were treated with neoadjuvant radiation at the University of Wisconsin (UW) between 1999 and 2012 were identified...
August 15, 2016: Cancer
Taejong Song, Chel Hun Choi, Mi Kyoung Kim, Mi-La Kim, Bo Seong Yun, Seok Ju Seong
To assess the current evidence on the potential benefit of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) on cancer recurrence and survival, we comprehensively searched PubMed, Embase, and the Cochrane Library from their inception to April 2013. Two authors screened out duplicates and independently reviewed the eligibility of each study. We included comparative studies comparing the use and nonuse of ACEIs or ARBs in cancer patients. Primary outcomes were disease-free survival (DFS) and overall survival...
January 2017: European Journal of Cancer Prevention
Yun-Tao Zhao, Peng-Yang Li, Jian-Qiang Zhang, Lei Wang, Zhong Yi
Angiotensin II receptor blockers (ARB) are widely used drugs that are proven to reduce cardiovascular disease events; however, several recent meta-analyses yielded conflicting conclusions regarding the relationship between ARB and cancer incidence, especially when ARB are combined with angiotensin-converting enzyme inhibitors (ACEI).We investigated the risk of cancer associated with ARB at different background ACEI levels.Search of PubMed and EMBASE (1966 to December 17, 2015) without language restriction.Randomized, controlled trials (RCTs) had at least 12 months of follow-up data and reported cancer incidence was included...
May 2016: Medicine (Baltimore)
Ji-Hyun Chin, Young-Jin Moon, Jun-Young Jo, Yun A Han, Hyeong Ryul Kim, Eun-Ho Lee, In-Cheol Choi
BACKGROUND: Newly developed atrial fibrillation (AF) in patients who have undergone an esophagectomy increases the incidence of postoperative complications. However, the clinical implications of AF have not been fully elucidated in these patients. This retrospective observational study investigated the predictors for AF and the effect of AF on the mortality in esophageal cancer patients undergoing esophagectomy. METHODS: This study evaluated 583 patients undergoing esophagectomy, from January 2005 to April 2012...
2016: PloS One
Abduelmenem Alashkham, Catherine Paterson, Phyllis Windsor, Allan Struthers, Petra Rauchhaus, Ghulam Nabi
BACKGROUND: Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are linked to prostate cancer, but their effect on biochemical recurrence (BR) remains unknown. Our aims were to investigate the incidence and risk of BR in men on ACEIs/ARBs after radical radiotherapy with adjuvant∖neoadjuvant hormone treatment. MATERIAL AND METHODS: A propensity score analysis of 558 men was conducted. Men were stratified into 3 groups: hypertensive men on ACEIs/ARBs (as a study group), non-hypertensive men not on ACEIs/ARBs, and hypertensive men not on ACEIs/ARBs (both as a control group)...
March 12, 2016: Clinical Genitourinary Cancer
M R Jones, K A Schrader, Y Shen, E Pleasance, C Ch'ng, N Dar, S Yip, D J Renouf, J E Schein, A J Mungall, Y Zhao, R Moore, Y Ma, B S Sheffield, T Ng, S J M Jones, M A Marra, J Laskin, H J Lim
BACKGROUND: A patient suffering from metastatic colorectal cancer, treatment-related toxicity and resistance to standard chemotherapy and radiation was assessed as part of a personalized oncogenomics initiative to derive potential alternative therapeutic strategies. PATIENTS AND METHODS: Whole-genome and transcriptome sequencing was used to interrogate a metastatic tumor refractory to standard treatments of a patient with mismatch repair-deficient metastatic colorectal cancer...
May 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
Sara Raimondi, Edoardo Botteri, Elisabetta Munzone, Carlo Cipolla, Nicole Rotmensz, Andrea DeCensi, Sara Gandini
Breast cancer (BC) is the second leading cause of cancer death among women in Western Countries. Beta-blocker (BB) drugs, angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) were suggested to have a favorable role in the development and progression of BC. We have performed a meta-analysis to clarify the potential benefits of these drugs on BC survival. A total number of 46 265 BC patients from eleven papers were included, ten independent studies on BB use and seven on ACEi/ARB use...
July 1, 2016: International Journal of Cancer. Journal International du Cancer
Todd A Mackenzie, Rebecca Zaha, Jeremy Smith, Margaret R Karagas, Nancy E Morden
OBJECTIVE: Patients with type II diabetes have an increased risk of bladder cancer and are commonly treated with thiazolidinediones and angiotensin receptor blockers (ARBs), which have been linked to cancer risk. We explored the relationship between use of one or both of these medication types and incident bladder cancer among diabetic patients (diabetics) enrolled in Medicare. RESEARCH DESIGN AND METHODS: We constructed both a prevalent and incident retrospective cohort of pharmacologically treated prevalent diabetics enrolled in a Medicare fee-for-service plan using inpatient, outpatient (2003-2011) and prescription (2006-2011) administrative data...
March 2016: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
Lili Miao, Wei Chen, Ling Zhou, Huanying Wan, Beili Gao, Yun Feng
It has been shown that angiotensin I-converting enzyme inhibitors (ACEIs) and angiotensin II type-1 receptor blockers (ARBs) can decrease tumor growth and tumor-associated angiogenesis and inhibit metastasis. Epidermal growth factor receptor (EGFR) mutations are found in approximately 30% of patients with advanced non-small cell lung cancer (NSCLC) in East Asia and in 10-15% of such patients in Western countries. We retrospectively identified 228 patients with histologically confirmed advanced NSCLC and 73 patients with early stage disease; 103 of these patients took antihypertensive drugs, and 112 received treatment with EGFR tyrosine kinase inhibitors (TKIs)...
2016: Scientific Reports
Mugdha Gokhale, Cynthia Girman, Yong Chen, Virginia Pate, Michele Jonsson Funk, Til Stürmer
PURPOSE: Differential diagnostic evaluation associated with a drug may bias effect estimates because of an increased detection of preclinical outcomes. Persistent cough is a common side effect with angiotensin-converting enzyme inhibitors (ACEI), and we hypothesized that ACEI initiators would undergo more diagnostic evaluations, potentially leading to diagnosis of preclinical lung cancer. We compared the incidence of cough-related diagnostic evaluations and lung cancer among ACEI versus angiotensin receptor blockers (ARB) initiators...
May 2016: Pharmacoepidemiology and Drug Safety
Hiroki Osumi, Satoshi Matsusaka, Takeru Wakatsuki, Mitsukuni Suenaga, Eiij Shinozaki, Nobuyuki Mizunuma
The local renin-angiotensin system promotes angiogenesis and vascular proliferation via expression of vascular endothelial growth factor or epidermal growth factor receptor. We hypothesized that angiotensin II type-1 receptor blockers (ARBs) in combination with bevacizumab (Bev) may improve clinical outcomes in patients with metastatic colorectal cancer (mCRC). A total of 181 patients with histopathologically confirmed mCRC treated with first-line oxaliplatin-based chemotherapy in combination with Bev were enrolled between June, 2007 and September, 2010...
November 2015: Molecular and Clinical Oncology
Samuel J Tingle, John A Moir, Steven A White
AIM: To investigate the survival impact of common pharmaceuticals, which target stromal interactions, following a pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. METHODS: Data was collected retrospectively for 164 patients who underwent a pancreaticoduodenectomy for pancreatic ductal adenocarcinoma (PDAC). Survival analysis was performed on patients receiving the following medications: angiotensin-converting enzyme inhibitors (ACEI)/angiotensin II receptor blockers (ARB), calcium channel blockers (CCB), aspirin, and statins...
November 15, 2015: World Journal of Gastrointestinal Pathophysiology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"